Site-directed mutagenesis of vasoactive intestinal peptide (VIP) receptor subtypes VIP1 and VIP2. Difference in their structure-function relationship;Mutagenese dirigee des recepteurs recombinants humains du peptide intestinal vasoactif (VIP) de type VIP1 et VIP2. Difference de relation structure-activite

Gastroenterologie Clinique et Biologique

Volumn 21, Issue 5, 1997, Pages 365-369

  Nicole, Pascal ^a   Du, Kai ^a   Couvineau, Alain ^a   Laburthe, Marc ^a  

^a INSERM   (France)

Author keywords

receptors; site directed mutagenesis; structure function relationship; vasoactive intestinal peptide; VIP

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; ALANINE; GLUTAMIC ACID; ISOLEUCINE; THREONINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; METHODOLOGY; MUTAGENESIS; STRUCTURE ACTIVITY RELATION; BINDING SITE; CHEMISTRY; CLASSIFICATION; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS;

ALANINE; BINDING SITES; GLUTAMIC ACID; HUMANS; ISOLEUCINE; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; STRUCTURE-ACTIVITY RELATIONSHIP; THREONINE;

EID: 0030634826     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Fahrenkrug J. Vasoactivc intestinal peptide. In : Makhlouf GM, ed. Handbook of Physiology, Section 6: The Gastrointestinal system, Vol II-Neural and endocrine biology. American Physiological Society, Bethesda, 1989:611-29.
2. Laburthe M, Amiranoff B. Peptide receptors in intestinal epithelium. In: Makhlouf GM, ed. Handbook of Physiology, Section 6: The Gastrointestinal system, Vol II-Neural and endocrine biology. American Physiological Society, Bethesda, 1989:215-43.
3. Laburthe M, Kitabgi P, Couvineau A, Amiranoff B. Peptide receptors and signal transduction in the digestive tract. Handbook Exp Pharmacol 1993;106:133-76.
4. Laburthe M, Rousset M, Boissard C, Chevalier G, Zweibaum A, Rossclin G. Vasoactive intestinal peptidc (VIP): a potent stimulator of adenosine 3′5′: cyclic monophosphate accumulation in gut carcinoma cell lines in culture. Proc Natl Acad Sci USA 1978;75:2772-5.
5. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992;8:811-9.
6. Couvineau A, Rouyer-Fessard C, Darmoul D, Maoret JJ, Carrero I, Ogier-Denis E et al. Human intestinal VIP receptors: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun 1994;200:769-6.
7. Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, Harmar AJ. The VIP2 receptor: molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 1993;334:3-8.
8. Svoboda M, Tastenoy M, Van Rampelbergh J, Goosens JF, De Neef P, Waelbroeck M et al. Molecular cloning and functional charaterization of a human receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 1994;205:1617-24.
9. Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 1994;135:2662-80.
10. Laburthe M, Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P. Receptors for VIP, PACAP, secretin, glucagon, GLP-1 and other receptors of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP1 receptor. Ann N Y Acad Sci 1996;805:94-109.
11. Laburthe M, Couvineau A, Voisin T. Receptors for peptides of the VIP/PACAP and PYY/NPY/PP families. In: Greeley GH, ed. Endocrinology of the Gastrointestinal System. The Humana Press, Inc., 1997 (in press).
12. Gaudin P, Couvineau A, Maorel JJ, Rouyer-Fessard C, Laburthe M. Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) receptor identifies seven mutants that are defective in VIP binding. Biochem Biophys Res Commun 1995;211:901-8.
13. Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P, Laburthe M. Highly conserved aspartate 68, tryptophan 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP. Biochem Biophys Res Commun 1995;206:246-52.
14. Du K, Nicole P, Couvineau A, Laburthe M. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production. Biochem Biophys Res Commun 1997;230:289-92.
15. Couvineau A, Fabre C, Gaudin P, Maoret JJ, Laburthe M. Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane. Biochemistry 1996;35:1745-52.
16. Couvineau A, Rouyer-Fessard C, Maoret JJ, Gaudin P, Nicole P, Laburthe M. Vasoactive intestinal peptide (VIP) 1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isolcucineamide. J Biol Chem 1996;271:12795-800.
17. Munson PJ, Rodbard D, Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980;107:220-39.
18. Hayes SA, Dice JF. Roles of molecular chaperones in protein folding. J Cell Biol 1996;132:255-8.